LUGANO, 26 April 2018 – ESMO, the leading professional organisation for medical oncology, shares concerns expressed in a scientific paper (1) and reflected in the international media about the rising costs of cancer medicines.
The authors of The Journal of Oncology Practice paper (1) used both the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2) and ASCO’s Value Framework to assess whether the clinical benefits of novel anticancer drugs have increased over time in parallel with increasing pricing. The authors concluded that while costs of these have risen over the past decade, their clinical benefit has not improved proportionally.
The ESMO-MCBS uses a rational, structured and consistent approach to grade the magnitude of clinical benefit that can be expected from anticancer treatments.
Prof. Elisabeth de Vries, Chair of the ESMO Cancer Medicines Committee and the ESMO-MCBS Working Group, (3) said: “The ESMO-MCBS provides unbiased information to help guide physicians and decision makers to grade drugs newly approved by the European Medicines Agency (EMA) by assessing their clinical benefit. It is an important first step in the major and ongoing task of evaluating value in cancer care which is essential for the appropriate use of limited public funds in delivering
Article originally posted at